During year 6 of continuous treatment with BRIUMVI the annualized relapse rate was 0.012, equivalent to one relapse occurring every 83 years of patient treatment Overall safety profile of BRIUMVI remained consistent over 6 years of continuous treatment, …

Update on the US regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosis Paris, September 22, 2025. The US Food and Drug Administration (FDA) has extended by three months the target action date of its review of the new …

… patients with autoimmune diseases like multiple sclerosis and rheumatoid arthritis, suggesting that … type of vaccine, and any vaccine-associated adverse events. Of patients …

NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of multiple sclerosis (RMS), at the …

… for autoimmune diseases, such as multiple sclerosis. You can place an order …

… Trump administration—pandering to anti-vaccine activists—rolled back national access … . Now, in an increasingly anti-vaccine public health regime, Americans are … , lives in Florida and has multiple sclerosis. On September 26, he’ll …

By The Herald Editorial Board Nature abhors a vacuum, as does the practice of sound science-based public health. In the vacuum of doubt now surrounding the Centers for Disease Control and Prevention and its guidance around access to vaccines for covid-19 …

There’s quite a bit of confusion surrounding who is eligible for updated COVID-19 vaccines. It follows Health Secretary Robert F. Kennedy Jr.’s shifting comments on vaccines and the announcement that people who are under 65 and considered healthy need a …

Breakthrough research suggests ivermectin could treat multiple sclerosis amid growing advocacy for repurposed medicines A new study shows ivermectin reduces symptoms in an MS mouse model by modulating immune cells. The drug’s efficacy is linked to its …

Register for free to listen to this article Thank you. Listen to this article using the player above. ✖ Want to listen to this article for FREE? Complete the form below to unlock access to ALL audio articles. Scientists from La Trobe University and …